TBI-1401(HF10)

HF10 oncolytic herpes simplex virus type 1 · Takara Bio Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TBI-1401(HF10), covering 2017-07-02 to 2024-12-09. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma [Phase 2]

See pricing